Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Hazard Rate01:11

Hazard Rate

The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alpha-gal Immunoglobulin E Seroprevalence Among Blood Donors - 10 States, 2024-2025.

MMWR. Morbidity and mortality weekly report·2026
Same author

Red Blood Cell Transfusion Characteristics and Morbidity or Mortality in Very-Low-Birth-Weight Infants.

JAMA network open·2026
Same author

An international study on emerging arboviral infections and blood safety.

Transfusion·2026
Same author

First-time blood donor demographics and characteristics during the individual donor assessment versus 3-month deferral policies for high-risk behaviors.

Transfusion·2026
Same author

Integrated analysis of blood donor metabolic phenotypes and genetic traits on red blood cell transfusion effectiveness.

Blood. Red cells & iron·2026
Same author

Workflow‑Based Information Management Framework for Multicenter Research Studies: Design and Development.

Online journal of public health informatics·2026
Same journal

Conformational dynamics of pneumococcal polysaccharide conjugates drive UV-vis quantification errors and a strategy to enable UV-vis spectrophotometer quantification.

Biologicals : journal of the International Association of Biological Standardization·2026
Same journal

Refining the regulatory and ethics context of controlled human infection models - a stakeholder meeting report.

Biologicals : journal of the International Association of Biological Standardization·2026
Same journal

Longevity of humoral response in recipients of rabies pre-exposure prophylactic vaccination with Abhayrab®.

Biologicals : journal of the International Association of Biological Standardization·2026
Same journal

Collaborative studies to establish WHO International Reference Reagents for diphtheria and tetanus antitoxin for use in the flocculation test.

Biologicals : journal of the International Association of Biological Standardization·2026
Same journal

Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence - a meeting report.

Biologicals : journal of the International Association of Biological Standardization·2026
Same journal

Leveraging analytical and bioprocess platforms for biological product development and commercialization - A meeting report.

Biologicals : journal of the International Association of Biological Standardization·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Risk assessment and cost-effectiveness/utility analysis.

Michael Busch1, Mark Walderhaug, Brian Custer

  • 1Blood Systems Research Institute, San Francisco, CA, USA. mbusch@bloodsystems.org

Biologicals : Journal of the International Association of Biological Standardization
|February 27, 2009
PubMed
Summary
This summary is machine-generated.

Public health and transfusion medicine decision-making is evolving. Quantitative risk assessment and cost-effectiveness analysis offer clearer, more accountable methods for complex challenges like emerging diseases and new technologies.

More Related Videos

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

Related Experiment Videos

Last Updated: Jun 25, 2026

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents
07:05

Operant Protocols for Assessing the Cost-benefit Analysis During Reinforced Decision Making by Rodents

Published on: September 10, 2018

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods
13:04

Measuring the Subjective Value of Risky and Ambiguous Options using Experimental Economics and Functional MRI Methods

Published on: September 19, 2012

Area of Science:

  • Public Health
  • Transfusion Medicine
  • Health Economics

Background:

  • Traditional decision-making in public health and transfusion medicine relies heavily on experience and judgment, which can lack clarity and accountability.
  • Emerging diseases and advanced technologies present complex challenges, requiring more robust decision-making frameworks.
  • Transfusion medicine decisions are particularly intricate due to public health implications, safety expectations, and regulatory landscapes.

Purpose of the Study:

  • To introduce quantitative risk assessment and cost-effectiveness analysis methodologies.
  • To discuss the application of these quantitative methods in transfusion medicine.
  • To enhance decision-making clarity and accountability in public health and transfusion medicine.

Main Methods:

  • Introduction to risk assessment principles.
  • Explanation of cost-effectiveness analysis techniques.
  • Review of recent case studies applying these methods in transfusion medicine.

Main Results:

  • Quantitative risk assessment provides a structured approach to evaluating potential harms and benefits.
  • Cost-effectiveness analysis aids in resource allocation by comparing intervention costs to health outcomes.
  • These methods offer improved transparency and data-driven support for complex policy and technology adoption decisions.

Conclusions:

  • Quantitative risk assessment and cost-effectiveness analysis are valuable tools for modern public health and transfusion medicine.
  • Adoption of these methodologies can lead to more informed, accountable, and effective decision-making.
  • Further application and research in these areas are crucial for advancing blood safety and public health outcomes.